Clinical Trials
9 trialsNCT03737994 2026-04-23
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT04223596 2026-02-04
CUBIK
Fundación GECP
Phase 2 Active not recruiting
NCT03707938 2025-11-03
Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT04227028 2025-09-16
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT04634110 2022-10-24
Brigatinib Before Brain Irradiation Trial (B3i Trial)
University of Colorado, Denver
Phase 2 Terminated
NCT04005144 2022-10-17
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
University of California, San Francisco
Phase 1 Terminated
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT02784158 2018-02-06
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
Takeda
No longer available